Receptor Life Sciences deal valued at $102.3 million

[yossarian]

Receptor Life Sciences apparently only has one deal according to www.biocentury.com/companies/receptor_life_sciences_inc
It is all in the form of milestone payments.  There is no upfront money. 

[kc]

Apr 12, 2016 13:51:27 GMT -5 yossarian said:

Receptor Life Sciences apparently only has one deal according to www.biocentury.com/companies/receptor_life_sciences_inc
It is all in the form of milestone payments.  There is no upfront money. 

Interesting it says the field is Neurology, Inflammation

I wonder if the neurology has anything to do with Alzheimer's ?

[cathode]

Apr 12, 2016 14:13:38 GMT -5 kc said:

Apr 12, 2016 13:51:27 GMT -5 yossarian said:

Receptor Life Sciences apparently only has one deal according to www.biocentury.com/companies/receptor_life_sciences_inc
It is all in the form of milestone payments.  There is no upfront money. 

Interesting it says the field is Neurology, Inflammation

I wonder if the neurology has anything to do with Alzheimer's ?

That website is not going to have any more information than what has been gathered on our message board.

[bmkb24]

Apr 12, 2016 14:13:38 GMT -5 kc said:

Apr 12, 2016 13:51:27 GMT -5 yossarian said:

Receptor Life Sciences apparently only has one deal according to www.biocentury.com/companies/receptor_life_sciences_inc
It is all in the form of milestone payments.  There is no upfront money. 

Interesting it says the field is Neurology, Inflammation

I wonder if the neurology has anything to do with Alzheimer's ?

IMO, as I stated in my other thread, it has Amgen written all over it... and here is the Amgen's current pipeline in those two areas... Just saying...

Therapeutic Area Neuroscience

AMG 581
Therapeutic Area Neuroscience - Modality Small Molecule
AMG 581 is a small molecule being investigated for the treatment of schizophrenia.

AMG 301
Therapeutic Area Neuroscience - Modality Monoclonal Antibody
AMG 301 is a monoclonal antibody being investigated for the treatment of migraine.

AMG 520
Therapeutic Area Neuroscience - Modality Small Molecule.
AMG 520 (CNP520) is a small molecule inhibitor of BACE. It is being investigated for the prevention of Alzheimer’s Disease, with Phase 2 studies ongoing.

AMG 334
Therapeutic Area Neuroscience - Modality Monoclonal Antibody.
AMG 334 is a human monoclonal antibody that inhibits the receptor for calcitonin gene-related peptide. It is being investigated for the prophylaxis of migraine. Phase 3 studies in episodic migraine, and a Phase 2 study in chronic migraine, are ongoing.


Therapeutic Area Inflammation

AMG 592
Therapeutic Area Inflammation - Modality Fusion Protein
AMG 592 is an IL-2 mutein Fc fusion protein. It is being investigated as a treatment for inflammatory diseases.

AMG 357
Therapeutic Area Inflammation - Modality Small Molecule
AMG 357 is a small molecule. It is being investigated as a treatment for autoimmune diseases.

AMG 557
Therapeutic Area Inflammation - Modality Monoclonal Antibody
AMG 557 is a human monoclonal antibody that inhibits the action of B7 related protein (B7RP-1). It is being investigated as a treatment for systemic lupus erythematosus.

AMG 157
Therapeutic Area Inflammation - Modality Monoclonal Antibody
AMG 157 is a human monoclonal antibody that inhibits the action of TSLP. It is being investigated as a treatment for asthma and atopic dermatitis, with Phase 2 studies ongoing.

AMG 181
Therapeutic Area Inflammation - Modality Monoclonal Antibody
AMG 181 is a human monoclonal antibody that inhibits the action of alpha4/beta7. It is being investigated as a treatment for ulcerative colitis and Crohn's disease, with Phase 2 studies ongoing.

Enbrel® (etanercept)
Therapeutic Area Inflammation - Modality Fusion Protein
ENBREL is a fusion protein that inhibits tumor necrosis factor. A Phase 3 study to evaluate ENBREL as a monotherapy for psoriatic arthritis treatment is ongoing. A Phase 3 study to evaluate ENBREL as a monotherapy in maintaining remission in rheumatoid arthritis is ongoing.

[scottiemac]

I'd say for migraine - one of Al's pet causes as his spouse suffers from them. Fast relief would be a blessing.

[bradleysbest]

bmkb that does seem to make sense. However, I thought a lot of things made sense the past couple of years & very few turned out to be worth anything...

[daduke38]

After hearing so many possible scenarios over the past few years, I have come to take most with a grain of salt.  However, I have to admit this Amgen thing might be the real deal.  Just too many things that seem to tie in. Just my 2 cents on a nice up day!

[daduke38]

Apr 12, 2016 15:23:17 GMT -5 bradleysbest said:

bmkb that does seem to make sense. However, I thought a lot of things made sense the past couple of years & very few turned out to be worth anything...

That is too funny!  We were basically posting the same thought at virtually the exact same time!

[bradleysbest]

Hopefully our day comes soon. Great minds think alike!

[dreamboatcruise]

Apr 12, 2016 14:51:26 GMT -5 cathode said:

Apr 12, 2016 14:13:38 GMT -5 kc said:

Interesting it says the field is Neurology, Inflammation

I wonder if the neurology has anything to do with Alzheimer's ?

That website is not going to have any more information than what has been gathered on our message board.

Did we know the value of the deal?  Clicking on it under deal details it makes it appear as if there may be more details if one has a subscription.  I don't suppose anyone has bothered to see if the free subscription trial actually gives access to more info.  Quite frankly I'm a little skeptical that they would have any financial details.

[peppy]

Apr 12, 2016 14:13:38 GMT -5 kc said:

Apr 12, 2016 13:51:27 GMT -5 yossarian said:

Receptor Life Sciences apparently only has one deal according to www.biocentury.com/companies/receptor_life_sciences_inc
It is all in the form of milestone payments.  There is no upfront money. 

Interesting it says the field is Neurology, Inflammation

I wonder if the neurology has anything to do with Alzheimer's ?

epilepsy

[cathode]

Apr 12, 2016 16:38:47 GMT -5 dreamboatcruise said:

Apr 12, 2016 14:51:26 GMT -5 cathode said:

That website is not going to have any more information than what has been gathered on our message board.

Did we know the value of the deal?  Clicking on it under deal details it makes it appear as if there may be more details if one has a subscription.  I don't suppose anyone has bothered to see if the free subscription trial actually gives access to more info.  Quite frankly I'm a little skeptical that they would have any financial details.

Press Release 2016-01-21

"MannKind will be eligible to receive development and commercialization milestones of up to $102.25 million as well as mid-single to low double-digit royalties on net sales of product."

[matt]

Apr 12, 2016 15:02:34 GMT -5 bmkb24 said:

Apr 12, 2016 14:13:38 GMT -5 kc said:

Interesting it says the field is Neurology, Inflammation

I wonder if the neurology has anything to do with Alzheimer's ?

IMO, as I stated in my other thread, it has Amgen written all over it... and here is the Amgen's current pipeline in those two areas... Just saying...

Therapeutic Area Neuroscience

AMG 581
Therapeutic Area Neuroscience - Modality Small Molecule
AMG 581 is a small molecule being investigated for the treatment of schizophrenia.

AMG 301
Therapeutic Area Neuroscience - Modality Monoclonal Antibody
AMG 301 is a monoclonal antibody being investigated for the treatment of migraine.

AMG 520
Therapeutic Area Neuroscience - Modality Small Molecule.
AMG 520 (CNP520) is a small molecule inhibitor of BACE. It is being investigated for the prevention of Alzheimer’s Disease, with Phase 2 studies ongoing.

AMG 334
Therapeutic Area Neuroscience - Modality Monoclonal Antibody.
AMG 334 is a human monoclonal antibody that inhibits the receptor for calcitonin gene-related peptide. It is being investigated for the prophylaxis of migraine. Phase 3 studies in episodic migraine, and a Phase 2 study in chronic migraine, are ongoing.


Therapeutic Area Inflammation

AMG 592
Therapeutic Area Inflammation - Modality Fusion Protein
AMG 592 is an IL-2 mutein Fc fusion protein. It is being investigated as a treatment for inflammatory diseases.

AMG 357
Therapeutic Area Inflammation - Modality Small Molecule
AMG 357 is a small molecule. It is being investigated as a treatment for autoimmune diseases.

AMG 557
Therapeutic Area Inflammation - Modality Monoclonal Antibody
AMG 557 is a human monoclonal antibody that inhibits the action of B7 related protein (B7RP-1). It is being investigated as a treatment for systemic lupus erythematosus.

AMG 157
Therapeutic Area Inflammation - Modality Monoclonal Antibody
AMG 157 is a human monoclonal antibody that inhibits the action of TSLP. It is being investigated as a treatment for asthma and atopic dermatitis, with Phase 2 studies ongoing.

AMG 181
Therapeutic Area Inflammation - Modality Monoclonal Antibody
AMG 181 is a human monoclonal antibody that inhibits the action of alpha4/beta7. It is being investigated as a treatment for ulcerative colitis and Crohn's disease, with Phase 2 studies ongoing.

Enbrel® (etanercept)
Therapeutic Area Inflammation - Modality Fusion Protein
ENBREL is a fusion protein that inhibits tumor necrosis factor. A Phase 3 study to evaluate ENBREL as a monotherapy for psoriatic arthritis treatment is ongoing. A Phase 3 study to evaluate ENBREL as a monotherapy in maintaining remission in rheumatoid arthritis is ongoing.

Not saying you are wrong about that, but pretty much every big pharma is going after these indications.  You can substitute Pfizer, Novartis, Glaxo, or Merck into the equation and not have a significantly different answer.  Anti-infectives were hot in the 1970's and 1980;s, metabolic drugs were hot in the 1990's and early 2000's, but not so much any more due to the explosion of generics as patents expired on the early ACE inhibitors, ARBs, statins and so forth.  Most pharmas moved on to monoclonals, neuro drugs, and cancer where pricing is still attractive, but it will be something totally different in ten years. 

It is just the product life cycle at work - station wagons gave way to minivans which gave way to SUVs.  I never even got my station wagon with the imitation wood panels on the side.

[prosper]

Does anyone know for what the $102.3M milestone payment is to be paid?

[mnholdem]

Only the parties know all the details, unfortunately. The only clues shareholders got was in the press release:

Under the terms of the agreement, MannKind will perform initial formulation studies and will work with Receptor to develop inhaled formulations of certain undisclosed compounds. MannKind will also transfer manufacturing technology to the licensee, who will be responsible for manufacturing and commercialization activities. The parties will collaborate on the clinical development of investigational products, with Receptor being responsible for all development costs. MannKind will be eligible to receive development and commercialization milestones of up to $102.25 million as well as mid-single to low double-digit royalties on net sales of product.  

See more at: investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=951141#sthash.FlNUrbFX.dpuf

The milestones are to be split into two activities:

• development
• commercialization

We don't know how many drugs will be developed or how the milestone payments are related to each drug. CEO Matt Pfeffer did state that it's possible that MannKind could receive a milestone payment from RLS by year's end.

Not much to go on...